Market Overview

The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron

The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron
Related XLRN
4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate
Benzinga's Top Upgrades, Downgrades For October 12, 2017
Acceleron's (XLRN) Acceleron ASH 2017 Update Conference (Transcript) (Seeking Alpha)
  • Acceleron Pharma Inc (NASDAQ: XLRN) shares have plunged 23 percent since December 21.
  • Credit Suisse’s Kennen MacKay initiated coverage of the company with an Outperform rating and a price target of $50.
  • The Street is less bullish about luspatercept due to competition from gene therapy.

Analyst Kennen MacKay believes that luspatercept has the potential to become a blockbuster drug, which could be a long-term treatment for beta-thal and MDS patients. He added, however, that the Street seems to be discounting the drug’s value due to potential competition from gene therapy in beta-thal.

Related Link: Credit Suisse Bullish On Most Big Pharma Names

Acceleron’s beta-thal phase 3 strategy “has been refined through lessons learned” from the phase 2 experience. This, together with recent gene therapy setbacks, supports peak sales estimate of $1 billion, MacKay commented. He added that there could be an additional $1 billion for RS+ MDS in which luspatercept exhibited the highest responses in phase 2.

In the report Credit Suisse noted, “Dalantercept + axitinib showed promising early ORR, PFS, and OS data in refractory RCC, nearly doubling PFS over SoC. We see potential for ~$900M in peak RCC sales…We also see this program as overlooked given its early-stage development, but we note the potential for rapid approval given the severity and lack of treatment options for refractory RCC patients.”

After closing up more than 5 percent on Wednesday, shares were down about 4.8 percent in Thursday's pre-market session.

Latest Ratings for XLRN

Nov 2017Credit SuisseMaintainsOutperform
Oct 2017H.C. WainwrightInitiates Coverage OnBuy
Sep 2017BarclaysMaintainsOverweight

View More Analyst Ratings for XLRN
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas Health Care Price Target Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (XLRN)

View Comments and Join the Discussion!

Partner Center